Search | JOV | ARVO Journals

Showing 1 – 20 of 72

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

Leveraging AI Chatbots to Transform Patient Education on Idiopathic Intracranial Hypertension

Qais Dihan; Andrew David Brown; Ana Zaldivar; Muhammad Z Chauhan; Taher K Eleiwa; Amr K Hassan; Ahmed B Sallam; Abdelrahman M Elhusseiny

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):350.

ARVO Annual Meeting Abstract June 2024

Large Language Models: A New Frontier in Pediatric Cataract Patient Education

Andrew David Brown; Qais Dihan; Muhammad Z Chauhan; Taher K Eleiwa; Amr K Hassan; Ahmed B Sallam; Abdelrahman M Elhusseiny

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):347.

ARVO Annual Meeting Abstract June 2024

Redefining Transplants: Bioengineering the Corneal Endothelium using Human Stem Cells & a Hydrogel Film.

Jaime Montenegro; Karl David Brown; John Finnigan; Paul Gurr; Greg Qiao; Raymond Wong; Greg Dusting; Mark Daniell

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):4140.

ARVO Annual Meeting Abstract June 2024

Role of Oral Methotrexate in Preventing Proliferative Vitreoretinopathy and Retinal Re-detachment

Effie Z Rahman; Charles Clifton Wykoff; David M Brown; Rajiv Shah

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):923.

ARVO Annual Meeting Abstract June 2024

Long-term efficacy and Safety of CT-P42 compared to Reference Aflibercept in Diabetic Macular Edema: 52-Week Results from the Phase 3 CT-P42

Paulo-Eduardo Stanga; Sebastian Wolf; Milan Veselovsky; Miroslav Veith; Andras Papp; Shobhana Mange; Lakshikanta Mondal; Sunghyun Kim; Keumyoung Ahn; Suyoung Kim; Dain Son; Hyejin Kang; Hyunjin Lee; David M Brown

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):4907.

ARVO Annual Meeting Abstract June 2024

Geographic atrophy progression in routine clinical practice: before and after pegcetacoplan treatment

Jessica Anning Cao; Calvin Wayne Wong; Sandro De Zanet; Natasa Jovic; Patrick Steiner; Sagar Patel; Mathew W MacCumber; David M Brown; Charles Clifton Wykoff

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):4396.

ARVO Annual Meeting Abstract June 2023

Functionalising a PEG-based Hydrogel Scaffold Improves Human Corneal Endothelial Cell Culture for Tissue-engineered Endothelial Keratoplasty.

Karl David Brown; Jason Palmer; John Finnigan; Paul Gurr; Jaime Montenegro; Greg Dusting; Greg Qiao; Mark Daniell

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):3812.

ARVO Annual Meeting Abstract June 2023

Addition of Blue Reflectance Image to Red Green 200° Ultra-widefield Images

Barbra Hamill; Tunde Peto; Lloyd P Aiello; SriniVas R Sadda; Anne Marie Cairns; Dana Keane; Jessica Carnevale; Mark Hope; Michael Johnson; David M Brown

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):5017.

ARVO Annual Meeting Abstract June 2023

Safety and Tolerability Study of Suprachoroidal Injection CLS-AX in Neovascular AMD Patients with Persistent Activity Following Anti-VEGF Therapy (OASIS, NCT04626128; Extension Study NCT NCT05131646)

Dennis M Marcus; Allen Hu; Mark Barakat; David M Brown; Rahul N Khurana; Joel Pearlman; Charles Clifton Wykoff; Thomas A Ciulla

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):728.

ARVO Annual Meeting Abstract June 2023

Baseline Disease Characteristics of Patients Who Maintained 12- and 16-Week Aflibercept 8 mg Dosing Versus Patients with Shortened Treatment Intervals Through Week 48 in the Phase 2/3 PHOTON Trial

David M Brown

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2813.

Retina June 2022

The Association of Fluid Volatility With Subretinal Hyperreflective Material and Ellipsoid Zone Integrity in Neovascular AMD

PDF

Justis P. Ehlers; Nikhil Patel; Peter K. Kaiser; Jeffrey S. Heier; David M. Brown; Xiangyi Meng; Jamie Reese; Leina Lunasco; Thuy K. Le; Ming Hu; Sunil K. Srivastava
TAGS: exudative age-related macular degeneration, eye, personal integrity, volume, attenuation
Invest. Ophthalmol. Vis. Sci.. 2022; 63(6):17. https://doi.org/10.1167/iovs.63.6.17

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2022

Evaluation of 8 mg Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration: Results from the Phase 2 CANDELA Study

David M Brown

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1345 – F0179.

ARVO Annual Meeting Abstract June 2022

A Phase I/IIa trial examining the safety and efficacy of BI-X in patients with diabetic macular ischemia and diabetic retinopathy: The HORNBILL study

Sobha Sivaprasad; Quan Dong Nguyen; Chirag Jhaveri; Harsha Sen; David M Brown; Raj K Maturi; Abosede Cole; Andrea Giani; Elizabeth Pearce

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):2308.

ARVO Annual Meeting Abstract June 2022

Brolucizumab for treatment of diabetic macular edema (DME): 100-week results from the KESTREL and KITE studies

Charles Clifton Wykoff; Justus G Garweg; Carl Regillo; eric souied; Sebastian Wolf; Dilsher Dhoot; Hansjüergen T Agostini; Andrew Chang; Augustinus Laude; Lidija Kovacic; Lixin Wang; Ying Wang; Emmanuel Bouillaud; David M Brown

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3849.

ARVO Annual Meeting Abstract June 2021

Correlation of Intraocular Cytokine Expression with Quantitative Ultra-widefield Fluorescein Angiographic Features in the IMAGINE Retinal Vein Occlusion Study

Alison Martin; Joseph Roy Abraham; Charles Clifton Wykoff; Leina Lunasco; Sruthi Arepalli; Sunil K. Srivastava; Christopher J. Mugnaini; Ming Hu; Jamie Reese; David M Brown; Justis P Ehlers

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):2169.

ARVO Annual Meeting Abstract June 2021

Macular Thickness Fluctuation as Biomarker: Impact on Visual Acuity Following Anti-VEGF Therapy for Diabetic Macular Edema

Jae Eun Lee; Hannah Yu; Stephen Laswell; David M Brown; Charles Clifton Wykoff

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):2553.

ARVO Annual Meeting Abstract June 2021

Computational Imaging Biomarker Correlation with Intraocular Cytokine Expression in Diabetic Macular Edema: Findings from the IMAGINE DME Study

Sudeshna Sil Kar; Joseph Roy Abraham; Charles Clifton Wykoff; Duriye Damla Sevgi; Leina Lunasco; David M Brown; Sunil K. Srivastava; Anant Madabhushi; Justis P Ehlers

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):2513.

ARVO Annual Meeting Abstract June 2021

Posterior Vitreous Detachment Assessment by Age Using Circumpapillary Optical Coherence Tomography

Stephen Laswell; Charles Clifton Wykoff; David M Brown

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):2461.

ARVO Annual Meeting Abstract June 2021

Brolucizumab for the treatment of visual impairment due to diabetic macular edema: 52-week results from the KITE and KESTREL studies

David M Brown; Sebastian Wolf; Justus Garweg; Francesco Bandello; Andres Emanuelli; Jose Juan Escobar Barranco; Joao Figueira; Vishali Gupta; Nor Fariza Ngah; Gerald Liew; Raman Tuli; Lixin Wang; Emmanuel Bouillaud; Eric Souied

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1045.

ARVO Annual Meeting Abstract June 2021

Safety of intravitreal pegcetacoplan in patients with neovascular age-related macular degeneration receiving anti-VEGF therapy

Allen Hu; Daniel Esmaili; Ramiro Ribiero; Caleb Bliss; Daniel Jones; David M Brown

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):427.

1 2 3 4

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Leveraging AI Chatbots to Transform Patient Education on Idiopathic Intracranial Hypertension

Large Language Models: A New Frontier in Pediatric Cataract Patient Education

Redefining Transplants: Bioengineering the Corneal Endothelium using Human Stem Cells & a Hydrogel Film.

Role of Oral Methotrexate in Preventing Proliferative Vitreoretinopathy and Retinal Re-detachment

Long-term efficacy and Safety of CT-P42 compared to Reference Aflibercept in Diabetic Macular Edema: 52-Week Results from the Phase 3 CT-P42

Geographic atrophy progression in routine clinical practice: before and after pegcetacoplan treatment

Functionalising a PEG-based Hydrogel Scaffold Improves Human Corneal Endothelial Cell Culture for Tissue-engineered Endothelial Keratoplasty.

Addition of Blue Reflectance Image to Red Green 200° Ultra-widefield Images

Safety and Tolerability Study of Suprachoroidal Injection CLS-AX in Neovascular AMD Patients with Persistent Activity Following Anti-VEGF Therapy (OASIS, NCT04626128; Extension Study NCT NCT05131646)

Baseline Disease Characteristics of Patients Who Maintained 12- and 16-Week Aflibercept 8 mg Dosing Versus Patients with Shortened Treatment Intervals Through Week 48 in the Phase 2/3 PHOTON Trial

The Association of Fluid Volatility With Subretinal Hyperreflective Material and Ellipsoid Zone Integrity in Neovascular AMD

Evaluation of 8 mg Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration: Results from the Phase 2 CANDELA Study

A Phase I/IIa trial examining the safety and efficacy of BI-X in patients with diabetic macular ischemia and diabetic retinopathy: The HORNBILL study

Brolucizumab for treatment of diabetic macular edema (DME): 100-week results from the KESTREL and KITE studies

Correlation of Intraocular Cytokine Expression with Quantitative Ultra-widefield Fluorescein Angiographic Features in the IMAGINE Retinal Vein Occlusion Study

Macular Thickness Fluctuation as Biomarker: Impact on Visual Acuity Following Anti-VEGF Therapy for Diabetic Macular Edema

Computational Imaging Biomarker Correlation with Intraocular Cytokine Expression in Diabetic Macular Edema: Findings from the IMAGINE DME Study

Posterior Vitreous Detachment Assessment by Age Using Circumpapillary Optical Coherence Tomography

Brolucizumab for the treatment of visual impairment due to diabetic macular edema: 52-week results from the KITE and KESTREL studies

Safety of intravitreal pegcetacoplan in patients with neovascular age-related macular degeneration receiving anti-VEGF therapy

To View More...

You must be signed into an individual account to use this feature.